Supplementary Data: Figure S1-3 and Table S1-S5 from Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

Authors:
  • AAAdnan O. Abu-Yousif
    Adnan O. Abu-Yousif
  • DCDonna Cvet
    Donna Cvet
  • MGMelissa Gallery
    Melissa Gallery
  • BBBret M. Bannerman
    Bret M. Bannerman
  • MGMichelle L. Ganno
    Michelle L. Ganno
  • MSMichael D. Smith
    Michael D. Smith
  • TKThomas A. Keating
    Thomas A. Keating
  • BSBradley Stringer
    Bradley Stringer
  • AKAfrand Kamali
    Afrand Kamali
  • SKSecil Koseoglu
    Secil Koseoglu

Abstract
Supplemental Figure 1: heavy and light chain sequences for 5F9, the human IgG1 monoclonal antibody (mAb) targeting the extracellular domain of GCC as described previously Supplemental Figure 2: Characterization of TAK-164 and chKTI-DGN549 by A) SDS PAGE gel and B) by Liquid chromatography-mass spectrometry (LC-MS) Supplemental Figure 3: In vivo activity of TAK-164 in PHTXM-46C Supplemental Table 1: Growth rate inhibition following treatment with TAK-164 and B) chKTI-ADC in PHTX and cell derived xenograft models Supplemental Table 2: Growth Rate Inhibition and associated statistics for HEK293 GCC#2 Supplemental Table 3: Growth Rate Inhibition and associated statistics for PHTX-09C Supplemental Table 4: Growth Rate Inhibition and associated statistics for PHTX-17C Supplemental Table 5: Growth Rate Inhibition and associated statistics for PHTX-11C